Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: Analysis of three clinical trials

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1547-1553

  Som, A ^a   Tu, S M ^a   Liu, J ^b   Wang, X ^b   Qiao, W ^b   Logothetis, C ^a   Corn, P G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

bone; metastases; predictive biomarkers; prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; DASATINIB; DOCETAXEL; DOXORUBICIN; IMATINIB; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BONE TURNOVER; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE NEOPLASMS; BONE REMODELING; COLLAGEN TYPE I; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867901154     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.436     Document Type: Article

References (30)

1. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 118(1): 63-71
2. Armstrong AJ, Febbo PG (2009) Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 14(8): 816-827
3. Bilen MA, Liu D, Mathew P, Pagliaro LC, Logothetis CJ, Araujo J, Aparicio A, Corn PG, Hadjenberg J, Dakhil SR, Tu S (2011) A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer. J Clin Oncol 29(suppl) abstract 4649
4. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR (2006) Markers of bone metabolism and survival in men with hormonerefractory metastatic prostate cancer. Clin Cancer Res 12(11 Pt 1): 3361-3367
5. Dayyani F, Gallick GE, Logothetis CJ, Corn PG (2011) Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103(22): 1665-1675
6. Dotan ZA (2008) Bone imaging in prostate cancer. Nat Clin Pract Urol 5(8): 434-444
7. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6): 637-643
8. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet 377(9768): 813-822
9. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Hass NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small E, Spira A, Vaishampayan U, Vogelzang N, Scheffold C, Ballinger MD, Schimmoller F, Smith DC (2011) Cabozantinib (XL184) in metastatic castrationresistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. ASCO (suppl): abstract 4516
10. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 4(7): 1765-1772
11. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113(1): 193-201
12. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1): 21-28
13. Logothetis CJ, Navone NM, Lin SH (2008) Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 14(6): 1599-1602
14. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ (2007) Plateletderived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19): 5816-5824
15. Messiou C, Collins DJ, Giles S, de Bono JS, Bianchini D, de Souza NM (2011) Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. Eur Radiol 21(10): 2169-2177
16. Messiou C, Cook G, deSouza NM (2009) Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 101(8): 1225-1232
17. Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiencho PJ, Logue JP, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, Coleman RE, Vogelzang NJ, O'Bryan-Tear CG, Garcia-Vargas JE, Shan M, Sartor AO (2012) Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol (suppl): abstract LBA4512
18. Pollen JJ, Witztum KF, Ashburn WL (1984) The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 142(4): 773-776
19. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebocontrolled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19): 1458-1468
20. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17(3): 948-957
21. Sadik M, Jakobsson D, Olofsson F, Ohlsson M, Suurkula M, Edenbrandt L (2006) A new computer-based decision-support system for the interpretation of bone scans. Nucl Med Commun 27(5): 417-423
22. Sartor O (2004) Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 6(Suppl 10): S3-S12
23. Sartor O, Goeckeler W, Bruland O (2011) Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian J Androl 13(6): 783-784
24. Saylor PJ, Lee RJ, Smith MR (2011) Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29(27): 3705-3714
25. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7): 1148-1159
26. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23(32): 8253-8261
27. Smith MR, Egerdie B, Hernandez TN, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8): 745-755
28. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345(13): 948-955
29. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van PH, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2011) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810): 39-46
30. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357(9253): 336-341